Cognitive Changes After Adjuvant Treatment in Older Adults with Early-Stage Breast Cancer.
Aging
Breast neoplasms
Chemotherapy
Cognition disorders
Cognitive changes
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
30
10
2017
accepted:
17
04
2018
pubmed:
24
6
2018
medline:
25
3
2020
entrez:
24
6
2018
Statut:
ppublish
Résumé
Group-based trajectory modeling is particularly important to identify subgroups of patients with pathological cognitive changes after cancer treatment. To date, only one study has explored cognitive trajectories in older patients with cancer. The present article describes objective cognitive changes before to after adjuvant treatment in older adults with early-stage breast cancer (EBC) after adjuvant treatment compared with healthy controls. Participants were patients ≥65 years of age with newly diagnosed EBC and healthy controls (age-, sex-, and education-matched). The pretreatment assessment was conducted before adjuvant therapy, and the post-treatment assessment after the end of the first adjuvant treatment. Objective cognitive changes before to after treatment were evaluated based on the Reliable Change Index for cognitive decline accounting for cognitive impairment status. The sample consisted of women newly diagnosed with EBC ( This study described for the first time objective cognitive changes before to after treatment of older adults with EBC immediately after the end of adjuvant treatment. A longer-term remote follow-up of adjuvant treatment is needed to better understand the cognitive trajectories of older patients with EBC. After the end of adjuvant treatment, 31% of older adults with early-stage breast cancer without initial objective cognitive impairment developed impairment, and 6% experienced accelerated cognitive decline. Initial cognitive functioning should be included in the balance of benefits and harms of systemic therapy for patients who are likely to be at highest risk for cognitive decline after cancer treatments. Regular cognitive follow-up of patients who had cognitive impairment before cancer treatment should monitor symptoms suggestive of neurodegenerative disease and avert the effect of cognitive disorders on patients' autonomy.
Sections du résumé
BACKGROUND
Group-based trajectory modeling is particularly important to identify subgroups of patients with pathological cognitive changes after cancer treatment. To date, only one study has explored cognitive trajectories in older patients with cancer. The present article describes objective cognitive changes before to after adjuvant treatment in older adults with early-stage breast cancer (EBC) after adjuvant treatment compared with healthy controls.
PATIENTS AND METHODS
Participants were patients ≥65 years of age with newly diagnosed EBC and healthy controls (age-, sex-, and education-matched). The pretreatment assessment was conducted before adjuvant therapy, and the post-treatment assessment after the end of the first adjuvant treatment. Objective cognitive changes before to after treatment were evaluated based on the Reliable Change Index for cognitive decline accounting for cognitive impairment status.
RESULTS
The sample consisted of women newly diagnosed with EBC (
CONCLUSION
This study described for the first time objective cognitive changes before to after treatment of older adults with EBC immediately after the end of adjuvant treatment. A longer-term remote follow-up of adjuvant treatment is needed to better understand the cognitive trajectories of older patients with EBC.
IMPLICATIONS FOR PRACTICE
After the end of adjuvant treatment, 31% of older adults with early-stage breast cancer without initial objective cognitive impairment developed impairment, and 6% experienced accelerated cognitive decline. Initial cognitive functioning should be included in the balance of benefits and harms of systemic therapy for patients who are likely to be at highest risk for cognitive decline after cancer treatments. Regular cognitive follow-up of patients who had cognitive impairment before cancer treatment should monitor symptoms suggestive of neurodegenerative disease and avert the effect of cognitive disorders on patients' autonomy.
Identifiants
pubmed: 29934409
pii: theoncologist.2017-0570
doi: 10.1634/theoncologist.2017-0570
pmc: PMC6324624
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
62-68Informations de copyright
© AlphaMed Press 2018.
Déclaration de conflit d'intérêts
Disclosures of potential conflicts of interest may be found at the end of this article.
Références
Breast Cancer Res Treat. 2017 Oct;165(3):677-686
pubmed: 28653250
J Behav Med. 2012 Feb;35(1):47-62
pubmed: 21487722
Arch Clin Neuropsychol. 2012 May;27(3):248-61
pubmed: 22382384
Eur J Cancer. 2014 Sep;50(13):2181-9
pubmed: 24958735
J Oncol Pract. 2017 Dec;13(12):784-790
pubmed: 29232539
Psychooncology. 2012 Nov;21(11):1141-8
pubmed: 23023994
Arch Clin Neuropsychol. 2001 Feb;16(2):183-91
pubmed: 14590186
Acta Neurol Belg. 1990;90(4):207-17
pubmed: 2124031
Oncologist. 2016 Nov;21(11):1337-1348
pubmed: 27473044
Lancet Oncol. 2011 Jul;12(7):703-8
pubmed: 21354373
Semin Oncol. 2013 Dec;40(6):709-25
pubmed: 24331192
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
CA Cancer J Clin. 2010 Mar-Apr;60(2):120-32
pubmed: 20173172
JAMA. 1993 May 12;269(18):2386-91
pubmed: 8479064
Support Care Cancer. 2011 Nov;19(11):1849-55
pubmed: 20957394
Future Oncol. 2017 Apr;13(9):767-771
pubmed: 28266247
Mov Disord. 2008 Jan 30;23(2):297-9
pubmed: 18044697
Am J Geriatr Psychiatry. 2009 Apr;17(4):281-90
pubmed: 19307857
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Cancer Treat Rev. 2014 Jul;40(6):810-7
pubmed: 24713425
Cancer. 2016 Nov 15;122(22):3555-3563
pubmed: 27447359
Stroke. 2010 Jun;41(6):1290-3
pubmed: 20378863
J Aging Health. 2009 Jun;21(4):567-80
pubmed: 19339680